First CAR T-Cell Therapy for Marginal Zone Lymphoma Gets FDA Green Light

(MedPage Today) — Patients with advanced marginal zone lymphoma (MZL) now benefit from CAR T cell therapy with FDA approval for lisocabtagene maraleucel (liso-cel, Breyanzi). The approval was supported by results from the TRANSCEND FL trial and states…